312: Maternal extracellular miRNAs as biomarkers for placental dysfunction between 17-28 weeks gestation by Herrero, Tiffany et al.
UC San Diego
UC San Diego Previously Published Works
Title
312: Maternal extracellular miRNAs as biomarkers for placental dysfunction between 
17-28 weeks gestation
Permalink
https://escholarship.org/uc/item/1b649640
Authors
Herrero, Tiffany
Olsen, Richelle
Leonardo, Trevor
et al.
Publication Date
2018
DOI
10.1016/j.ajog.2017.10.248
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ajog.org Poster Session IIand preeclampsia, we hypothesized that the administration of pra-
vastatin could attenuate the expected cardiac changes with hyper-
tensive disorders as demonstrated by the SRUPP model.
STUDY DESIGN: Pregnant Sprague-Dawley rats were allocated to one
of four groups: sham surgery (n¼12), SRUPP surgery (n¼12), sham
surgery with pravastatin (n¼9), and SRUPP surgery with pravastatin
(n¼10). On gestational day (GD) 13, all pregnant rats underwent
maternal echocardiography. On GD 14, the SRUPP surgery and
SRUPP surgery with pravastatin groups underwent laparotomy with
placement of silver clips on the uterine and utero-ovarian arteries
bilaterally. In the sham surgery groups, the uterine and utero-
ovarian vessels were isolated without placement of clips. The rats in
the pravastatin groups were administered 1 mg/kg pravastatin on GD
14 through 19. On GD 20, all pregnant rats underwent repeat
maternal echocardiography. Analysis of Variance (ANOVA) was used
for statistical analysis. Post hoc multiple comparison tests were
performed as well. A P value <0.05 indicated statistical signiﬁcance.
RESULTS: The echocardiogram parameters did not differ signiﬁcantly
among groups on GD 13. On GD 20, the cardiac output in the rats in
the SRUPP surgery group (64.67  2.03 mL/min) was signiﬁcantly
increased compared to the sham surgery group (49.35  3.58 mL/
min) (P ¼ 0.008). Additionally, the stroke volume differed signiﬁ-
cantly between the SRUPP surgery group (166.29  6.19 uL) and the
sham surgery group (135.20  9.35 uL) (P ¼ 0.047). While not
statistically signiﬁcant, the cardiac output (56.97  4.23 mL/min)
was decreased in the SRUPP surgery with pravastatin group as
compared to the SRUPP surgery group (P¼0.09).
CONCLUSION: Pravastatin may attenuate the expected changes in
cardiac function with hypertensive disorders as seen in the SRUPP
model of preeclampsia in rats.312 Maternal extracellular miRNAs as biomarkers
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OBJECTIVE: We used next-generation sequencing methods to identify
miRNAs in the extracellular RNA in the serum of patients between
17-28 weeks gestation in patients who developed placental
dysfunction (preeclampsia or intrauterine growth restriction)
compared to those with uncomplicated pregnancy outcomes.
STUDY DESIGN: Maternal serum was collected between 17-28 weeks
gestation from the UC San Diego Placental Dysfunction Clinic.
Subjects were referred to the clinic for abnormal analytes from ﬁrst
or second trimester serum aneuploidy screening or maternal co-
morbidites that increased their risk for placental dysfunction. 19
cases and 29 controls were selected from this cohort. Extracellular
RNA was isolated from the serum samples, and small RNA
sequencing libraries were constructed. Differential rank conservation
was used to identify extracellular miRNA biomarkers associated with
placental dysfunction.
RESULTS: The UCSD cohort was analyzed in two technical repli-
cates. To avoid normalization artifacts, ratios of pairs of miRNAs
were used as analytes. The performance of all possible pairs of
detected miRNAs was determined separately for the two technical
replicate datasets for this cohort. The 100 top performing miRNA
pairs from the ﬁrst technical replicate of the UCSD cohort wereSupplemselected for further analysis. There was an enrichment of miRNAs
encoded by two miRNA gene clusters on chromosomes 14 and 19,
both of which have been reported to be expressed in the placenta
in prior studies. The performance of all possible combinations of 5
pairs from these 100 top performing miRNA pairs were tested. The
best combinations of 5 miRNA pairs yielded a sensitivity of 94.4%
and speciﬁcity of 96% in the ﬁrst technical replicate and a sensi-
tivity of 93% and speciﬁcity of 89.5% in the second technical
replicate. The performance of these combinations in a sample set
including only normal versus severe preeclampsia cases only, and
obtained a sensitivity and speciﬁcity of 100% for the top per-
forming combinations in both the ﬁrst and second technical
replicates.
CONCLUSION: By isolating and performing small RNA sequencing on
extracellular RNA from maternal serum collected between 17-28
weeks gestation, we identiﬁed candidate biomarkers for placental
dysfunction miRNAs in the maternal serum. Future work will
include validation of these candidates in an independent cohort.313 Quantitative functional alterations in
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OBJECTIVE: Preeclampsia and HELLP syndrome share many clinical
and biologic features with thrombotic microangiopathy syndromes
caused by abnormalities in complement pathways. It is unclear
whether functional and genetic alterations in the complement
alternative pathway (CAP) are associated with preeclampsia and
HELLP syndrome.
STUDY DESIGN: We used prospectively collected blood samples (2012
to 2016) from cases of severe phenotype preeclampsia, deﬁned as
delivery <34 weeks, HELLP syndrome and eclampsia, and matched
normotensive controls (n¼25 in each arm). Quantitative and
functional analysis of 15 CAP components and activation fragments
was conducted using clinically available immunoassays. Whole
exome sequencing was performed on study group to interrogate 36
genes encoding CAP factors for coding non-synonymous sequence
variants with a population allele frequency of <5%.
RESULTS: Study and control groups were similar in age, gravidity,
parity, marital status and race. However, the study group had a
higher BMI (meanSD; 328 vs 254 kg/m2; p¼0.002) and earlier
gestational age at delivery (32.53.6 vs 40.31 weeks; p<0.001).
Serological studies in cases compared with controls demonstrated
elevated Bb subunit (median [range]; 1.2 [0.5-4.3] vs 0.6 [0.5-1]
mcg/mL; p<0.001), C5 concentrations (28 [18-33] vs 24 [15-34]
mg/dL; p¼0.03) and sMAC (371 [167-761] vs 184 [112-249] ng/mL;
p<0.001) levels. Of 25 cases, 17 (68%) had at least 1 sequence
variant in CAP genes (5 x CFB, 2 x CFI, 3 x CFH, 5 x CFHR, 1 x
MCP, 5 x C2, 3 x C3, 1 x C3R, 1x C5, 5 x C7, 5 x C8, 1x C9). Speciﬁc
listings are found in Figure.
CONCLUSION: Patients with severe phenotype preeclampsia manifest
functional alterations in complement alternative pathway activation,
as evident by elevated levels of Bb, C5 and sMAC. Associated genetic
sequence variants in complement pathway genes are also more
common than expected, some of which are potentially pathogenic,
suggesting shared genetic pathogenesis. Genetic screening andent to JANUARY 2018 American Journal of Obstetrics & Gynecology S197
